Results 181 to 190 of about 24,853 (244)

Clinical benefit and predictors of response to momelotinib after ruxolitinib failure: A cooperative real-world study. [PDF]

Cancer
Palandri F, Marchetti M, Elli EM, Isidori A, Gianesello I, Sartor C, Pugliese N, Di Perna M, Morsia E, Gallo S, Itri F, Montefusco V, Crisà E, Biagi A, Beggiato E, Mulas O, Benevolo G, Abruzzese E, Santoro M, Iurlo A, Calistri E, Rossi M, Martino B, Tiribelli M, Fava C, Dizdari A, Crugnola M, Duminuco A, Votto A, Guerzoni S, Caocci G, Pane F, Lanza F, Branzanti F, Dedola A, Salvatore F, Heidel FH, Breccia M, Palumbo GA, Kuykendall AT, Lucchesi A, Galimberti S.   +41 more
europepmc   +1 more source

Patients with steroid-refractory gastrointestinal aGVHD respond to ROCK2 inhibitor rapidly. [PDF]

Ann Hematol
Yue X, Li T, Zhao X, Wang S, Pan W, Yin X, Chen H, Xiao H.   +7 more
europepmc   +1 more source

Enhancing Alcelaphine gammaherpesvirus 1 propagation in the MDBK cell line: role of ruxolitinib and reduced incubation temperature. [PDF]

Vet Res Commun
Malenovská H.
europepmc   +1 more source

Ruxolitinib as an alternative to hydroxyurea in essential thrombocythemia in the setting of nonhealing ulcers. [PDF]

JAAD Case Rep
Ricke C, Ross F.
europepmc   +1 more source

Steroid-Refractory Chronic Graft-Versus-Host Disease-Associated Isolated Myositis Successfully Treated With Ruxolitinib: A Case Report. [PDF]

EJHaem
Kumamoto T, Yoshihara K, Matsuda I, Urase A, Ikunari R, Takahashi S, Samori M, Hirota S, Ohe C, Yoshihara S.   +9 more
europepmc   +1 more source

Linear Darier disease treated with ruxolitinib: Case report and review of the literature. [PDF]

JAAD Case Rep
Kahli JW, Martin P, Ezzell T.
europepmc   +1 more source

JAK1/2 inhibitor ruxolitinib reduces aggregates in cardiac proteinopathy. [PDF]

EMBO Mol Med
Alizoti E, Ewald L, Parretta S, March JJK, Meyer-Jens M, Orthey E, Conze C, Carrier L, Robbins J, Singh SR.   +9 more
europepmc   +1 more source

The Path Forward in MF: Small Molecules in the Limelight. [PDF]

Cancers (Basel)
Abruzzese E, Trawinska MM, Bernardi S, Checcoli A, Canichella M.   +4 more
europepmc   +1 more source

Rovadicitinib, a first-in-class JAK/ROCK inhibitor, in patients with myelofibrosis: a preclinical and phase I study. [PDF]

Blood Cancer J
Xu Z, Liu J, Hong Z, Yin Q, Zuo X, Wen Q, Li L, Chang C, Du X, Wang Y, Yang X, Yang C, Jia H, Pan L, Xiao Z.   +14 more
europepmc   +1 more source

Efficacy of ruxolitinib cream in a patient with lupus miliaris disseminatus faciei. [PDF]

JAAD Case Rep
Chevallier E, Cardot-Leccia N, Passeron T, Montaudié H.   +3 more
europepmc   +1 more source